DEVELOPMENT OF NOVEL, NON‐TOXIC RIFAMYCINS THAT REVERSE DRUG RESISTANCE IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (June 2017) - Maxwell, S.A.; Wallis, D.; Zhou, N.; Baker, D.; Mousavi‐Fard, S.; Loesch, K.; Galaviz, S.; Sun, Q.; Threadgill, D.M.; Rojas, C.M.; O'Brien, M.; Clubb, F.J.; et al.